The effect of metabolic dysfunction-associated steatotic liver disease on the disease progression in patients with COVID-19 associated pneumonia
Liver steatosis, regardless of other metabolic risk factors, increased the need for biological therapy, whereas the need for antibiotic therapy was a consequence of T2DM. Our study showed a more severe course of COVID-AP in people with MASLD and higher mortality.
Authors
- Philipp Roshchin (ORCID: https://orcid.org/0000-0002-9377-1394)
- Oleg Mestnikov
- Taisiia Turankova
- Dina Baimukhambetova (ORCID: https://orcid.org/0000-0002-5518-9301)
- Daria L Varganova (ORCID: https://orcid.org/0000-0002-5745-7605)
- A. Yu. Brazhnikov (ORCID: https://orcid.org/0000-0002-5587-8860)
- Marianna Semenistaia (ORCID: https://orcid.org/0000-0002-1724-4760)
- Chavdar S Pavlov
- Nadezhda G. Moroz
Institutions
- Botkin Hospital (RU)
Publication Details
- Journal
- Translational Gastroenterology and Hepatology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tgh-25-24
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00